Wealth Enhancement Advisory Services LLC Has $77.22 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Wealth Enhancement Advisory Services LLC raised its stake in Gilead by 6.4% in Q4 to 633,185 shares — valued at $77.22 million and representing roughly 0.05% of the company.
• Sell-side sentiment is largely positive: Gilead holds a consensus rating of "Moderate Buy" with an average target of $157.62, and several firms (including Morgan Stanley, Argus and BMO) have recently raised price targets.
• Gilead beat quarterly expectations (EPS $1.86 vs $1.83; revenue $7.93B vs $7.68B), set FY2026 guidance of 8.45–8.85 EPS, and raised its quarterly dividend to $0.82 (annual $3.28, yield 2.4%).

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 633,185 shares of the biopharmaceutical company's stock after buying an additional 37,949 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.05% of Gilead Sciences worth $77,219,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $215,000. Sivia Capital Partners LLC boosted its stake in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after buying an additional 602 shares during the period. Wealthspire Advisors LLC grew its holdings in shares of Gilead Sciences by 19.5% during the 2nd quarter. Wealthspire Advisors LLC now owns 2,681 shares of the biopharmaceutical company's stock valued at $297,000 after acquiring an additional 437 shares in the last quarter. Finally, Magnetar Financial LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $2,582,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Citigroup reiterated a "buy" rating on shares of Gilead Sciences in a report on Friday, March 6th. Morgan Stanley boosted their target price on Gilead Sciences from $150.00 to $171.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Wall Street Zen raised Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 14th. Argus raised their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $157.62.

Gilead Sciences Stock Down 2.8%

GILD stock opened at $137.21 on Monday. The firm has a market cap of $170.34 billion, a PE ratio of 20.27, a PEG ratio of 1.80 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a fifty day simple moving average of $142.69 and a 200 day simple moving average of $127.98. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The business's quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio (DPR) is 48.45%.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares of the company's stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 309,280 shares of company stock valued at $44,068,850 over the last 90 days. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.